TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27484082

Group type: EXPERIMENTAL
Intervention: Adjunctive steroid (triamcinolone acetonide) given at the time of surgery (4 mg/0.1 ml into the vitreous cavity and 40 mg/1 ml sub‐Tenon's).
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard surgical treatment and care (control group).
Number of subjects: 300
Study: 23842630

Group type: EXPERIMENTAL
Intervention: Computer-assisted total knee arthroplasty
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional jig-assisted total knee replacement
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both interventions (Computer-assisted and Conventional jig-assisted)
Number of subjects: 37
Study: 23867415

Group type: EXPERIMENTAL
Intervention: Individualized resting mitt splint
Number of subjects: 10

Group type: COMPARATOR
Intervention: No splint
Number of subjects: 10
Study: 20626379

Group type: EXPERIMENTAL
Intervention: Extended buprenorphine-naloxone (BUP) treatment
Number of subjects: 152

Group type: COMPARATOR
Intervention: Brief detoxification treatment (DETOX)
Number of subjects: 152
Study: 18058832

Group type: EXPERIMENTAL
Intervention: Galantamine augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo augmentation of standard antidepressant pharmacotherapy (venlafaxine XR or citalopram)
Number of subjects: 38
Study: 16822654

Group type: EXPERIMENTAL
Intervention: Computer-aided measurement of psoriatic lesion area
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adapted PASI index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12534638

Group type: EXPERIMENTAL
Intervention: Meloxicam administered once daily for 3 weeks or 6 months at doses between 7.5 and 60 mg
Number of subjects: 586
Study: 10375064

Group type: EXPERIMENTAL
Intervention: Health education plus brief counselling intervention
Number of subjects: 264

Group type: COMPARATOR
Intervention: Health education alone
Number of subjects: 264
Study: 8705294

Group type: EXPERIMENTAL
Intervention: Melanotransferrin in brain tissues from AD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transferrin receptor in brain tissues from AD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transferrin in brain tissues from AD patients
Number of subjects: 0
Study: 1866045

Group type: EXPERIMENTAL
Intervention: Calcium acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 0
Study: 6897039

Group type: EXPERIMENTAL
Intervention: Oral molsidomine 4 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sustained-release isosorbide dinitrate (ISDN) 40 mg
Number of subjects: 10
Study: 31733647

Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 353

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 353
Study: 30006977

Group type: EXPERIMENTAL
Intervention: Light microscopy using knizocyte visual cue
Number of subjects: 971

Group type: COMPARATOR
Intervention: Standard PCR genotyping
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Light microscopy (generalized mixed modeling)
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Light microscopy excluding error-prone reader
Number of subjects: 971
Study: 26818127

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsules (XFC), 3 pills three times daily for 2 months
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tripterygium glycoside (TPT), 2 pills three times daily for 2 months
Number of subjects: 80
Study: 24636358

Group type: EXPERIMENTAL
Intervention: 8 sessions of a group-based, community-participative, psychosocial intervention (n=79)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Wait-list control group (n=80)
Number of subjects: 159
Study: 22059409

Group type: EXPERIMENTAL
Intervention: Oral administration of selected lactobacilli up to the 24th to 26th week of gestation
Number of subjects: 644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 644
Study: 19037804

Group type: EXPERIMENTAL
Intervention: Capsinoids (15 mg/person)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsinoids (30 mg/person)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Capsinoids (15 or 30 mg/person)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 16935685

Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol (160 microg and 4.5 microg)
Number of subjects: 3394

Group type: EXPERIMENTAL
Intervention: As-needed formoterol (4.5 microg)
Number of subjects: 3394

Group type: COMPARATOR
Intervention: As-needed terbutaline (0.4 mg)
Number of subjects: 3394

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 3394
Study: 12617263

Group type: EXPERIMENTAL
Intervention: Interferon-beta-1a (Rebif) treatment
Number of subjects: 38
Study: 10871468

Group type: EXPERIMENTAL
Intervention: High-dose magnesium sulfate (5 g/h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose magnesium sulfate (2 g/h)
Number of subjects: 0
Study: 8926389

Group type: EXPERIMENTAL
Intervention: Radiotherapy (XRT) with hyperthermia (HT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Radiotherapy (XRT) without hyperthermia (HT)
Number of subjects: 23
Study: 1393304

Group type: EXPERIMENTAL
Intervention: moclobemide
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: phenelzine
Number of subjects: 78

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study: 4007253

Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine from source 1
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine from source 2
Number of subjects: 197
Study: 30560427

Group type: EXPERIMENTAL
Intervention: Federal monitoring lotteries program (audited municipalities)
Number of subjects: 1520

Group type: COMPARATOR
Intervention: Control group (non-audited municipalities)
Number of subjects: 1520
Study: 28362661

Group type: EXPERIMENTAL
Intervention: Standard colonoscopy in conjunction with fecal occult blood testing
Number of subjects: 63

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 63
Study: 25912590

Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 72
Study: 23262118

Group type: EXPERIMENTAL
Intervention: SMART‐OP (self‐guided, multimedia stress management and resilience training program)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Attention Control (AC) group (marketed videos and published material on stress management)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: SMART‐OP
Number of subjects: 66

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 66
Study: 21985278

Group type: EXPERIMENTAL
Intervention: Intervention group (7 schools)
Number of subjects: 1348

Group type: COMPARATOR
Intervention: Control group (7 schools)
Number of subjects: 1348
Study: 19157345

Group type: EXPERIMENTAL
Intervention: CIPCEA
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCEABI
Number of subjects: 60
Study: 17082219

Group type: EXPERIMENTAL
Intervention: Radical prostatectomy plus endocrine therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: External beam radiotherapy plus endocrine therapy
Number of subjects: 95
Study: 15535165

Group type: EXPERIMENTAL
Intervention: Arousing words presented at the periphery during encoding
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral words presented at the periphery during encoding
Number of subjects: 0
Study: 10912550

Group type: EXPERIMENTAL
Intervention: Peer counselling during antenatal and post-natal period
Number of subjects: 995

Group type: COMPARATOR
Intervention: Control group (no peer counselling)
Number of subjects: 995
Study: 9162292

Group type: EXPERIMENTAL
Intervention: Bemitil (0.5 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenibut (0.25 g)
Number of subjects: 0
Study: 8243522

Group type: EXPERIMENTAL
Intervention: Loxiglumide co-infused with bombesin
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline co-infused with bombesin
Number of subjects: 6
Study: 3753670

Group type: EXPERIMENTAL
Intervention: 16 mg nifalatide
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 48 mg nifalatide
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 30721208

Group type: EXPERIMENTAL
Intervention: Aflibercept administered as 1 injection every other month after 3 initial monthly doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pro Re Nata (PRN) regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observe-and-Plan (O&P) regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treat and Extend (T&E) regimen
Number of subjects: 0
Study: 27458584

Group type: EXPERIMENTAL
Intervention: Aprepitant (40 mg) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ondansetron (4 mg IV) + Dexamethasone (10 mg IV) + Promethazine (25 mg IV)
Number of subjects: 48
Study: 25525354

Group type: EXPERIMENTAL
Intervention: ELLIPTA® dry powder inhaler
Number of subjects: 150

Group type: COMPARATOR
Intervention: BREEZHALER™
Number of subjects: 150
Study: 22759932

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Cognitive Remediation (CR)
Number of subjects: 198
Study: 19996996

Group type: EXPERIMENTAL
Intervention: High-Intensity Progressive Resistance Training (HI PRT)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Power Training (PT)
Number of subjects: 1313

Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 1313
Study: 18245398

Group type: EXPERIMENTAL
Intervention: Prophylactic indomethacin
Number of subjects: 1202

Group type: COMPARATOR
Intervention: Serious pulmonary hemorrhage
Number of subjects: 1202
Study: 16449409

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Trauma scripts
Number of subjects: 39
Study: 12953801

Group type: EXPERIMENTAL
Intervention: Palatinose (5 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 0
Study: 11029566

Group type: EXPERIMENTAL
Intervention: Benzalkonium chloride catheter
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control catheter (polyurethane non-antiseptic)
Number of subjects: 235
Study: 8943171

Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Iodide substitution
Number of subjects: 107
Study: 1565347

Group type: EXPERIMENTAL
Intervention: 5-mg PGE2 gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Quartered 20-mg PGE2 suppository
Number of subjects: 90
Study: 3974797

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-Theophylline
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fullterm infants
Number of subjects: 37
Study: 31062697

Group type: EXPERIMENTAL
Intervention: MiStent
Number of subjects: 36

Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 36
Study: 31876741

Group type: EXPERIMENTAL
Intervention: Docetaxel and lobaplatin (DL)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Docetaxel and gemcitabine (DG)
Number of subjects: 43
Study: 29621064

Group type: EXPERIMENTAL
Intervention: Children with SCD‐SS
Number of subjects: 44
Study: 26282827

Group type: EXPERIMENTAL
Intervention: New algorithms for Masimo pulse oximeters
Number of subjects: 257

Group type: COMPARATOR
Intervention: Original Masimo oximeter software
Number of subjects: 257
Study: 25142262

Group type: EXPERIMENTAL
Intervention: Incentivised case finding for depression using two standard screening questions
Number of subjects: 140237

Group type: COMPARATOR
Intervention: Non-targeted patients (control group)
Number of subjects: 140237

Group type: EXPERIMENTAL
Intervention: Incentivised case finding for depression
Number of subjects: 140237
Study: 22492381

Group type: EXPERIMENTAL
Intervention: Ad libitum diets with different glycemic indexes and contents of dietary protein
Number of subjects: 742
Study: 19816213

Group type: EXPERIMENTAL
Intervention: Energy drink + exercise (EX-A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo + exercise (EX-B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Energy drink (NEX-A)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (NEX-B)
Number of subjects: 38
Study: 18822838

Group type: EXPERIMENTAL
Intervention: Lecture + tabletop exercise
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lecture only
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study: 15857078

Group type: EXPERIMENTAL
Intervention: SRP + AZM
Number of subjects: 31

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 31
Study: 12091845

Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg) nebulization, repeated every 2 hours until potassium level fell below 5 mmol/L (maximum 12 doses)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline nebulization (placebo)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Albuterol (400 microg) nebulization, repeated every 2 hours
Number of subjects: 19
Study: 10890262

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution BID
Number of subjects: 268

Group type: COMPARATOR
Intervention: Terfenadine 60-mg tablets BID
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: COMPARATOR
Intervention: Nedocromil sodium, Terfenadine, Placebo
Number of subjects: 268
Study: 7724098

Group type: EXPERIMENTAL
Intervention: Intravaginal prostaglandin E2 (PGE2) suppositories
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intramuscular 15-methyl-prostaglandin F2 alpha (15M-PGF2 alpha)
Number of subjects: 51
Study: 1776748

Group type: EXPERIMENTAL
Intervention: HP 128 (adrenergic/cholinergic agent) administered for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 6125918

Group type: EXPERIMENTAL
Intervention: Clorazepate with phenytoin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Phenobarbital with phenytoin
Number of subjects: 42
Study: 31897956

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) for remission induction and maintenance
Number of subjects: 17
Study: 31315114

Group type: EXPERIMENTAL
Intervention: Rivastigmine (1.5 mg for the first 7 days and 3 mg from day 8 to day 24)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 28647744

Group type: EXPERIMENTAL
Intervention: Supported self-help preventive cognitive therapy (S-PCT)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 248
Study: 27265548

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) - aripiprazole (10-20 mg), olanzapine (10-20 mg), or quetiapine (400-800 mg)
Number of subjects: 149

Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs) - haloperidol (3-6 mg) or flupentixol (6-12 mg)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 149

Group type: COMPARATOR
Intervention: First-generation antipsychotics (FGAs)
Number of subjects: 149
Study: 24394682

Group type: EXPERIMENTAL
Intervention: Intervention caregivers at 6 months
Number of subjects: 781

Group type: COMPARATOR
Intervention: Control caregivers at 6 months
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Intervention caregivers
Number of subjects: 781

Group type: COMPARATOR
Intervention: Control caregivers
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Intervention group (frequent feeders)
Number of subjects: 781
Study: 21695470

Group type: EXPERIMENTAL
Intervention: Divergent thinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Convergent thinking
Number of subjects: 0
Study: 19916263

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) with compression handpiece (CHP), 6 J/cm2, 6 msec pulse duration, three monthly treatments
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 595 nm pulsed dye laser (PDL) with compression handpiece (CHP)
Number of subjects: 10
Study: 17265038

Group type: EXPERIMENTAL
Intervention: Vasopressin (10 IU IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo IV (up to 3 injections at least 5 min apart)
Number of subjects: 0
Study: 15591642

Group type: EXPERIMENTAL
Intervention: Ketoprofen administered one hour before incision (PRE group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketoprofen administered immediately after surgery (POST group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NCA (Nurse Controlled Analgesia) for postoperative analgesia
Number of subjects: 60
Study: 11198531

Group type: EXPERIMENTAL
Intervention: MRI study at baseline and completion of the study
Number of subjects: 105

Group type: COMPARATOR
Intervention: Clinical score measures
Number of subjects: 105
Study: 10518857

Group type: EXPERIMENTAL
Intervention: Silver zeolite (SZ) mouthrinse at a concentration of 3% (w/w), rinsed twice a day for five days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Type-A zeolite mouthrinse (placebo), rinsed twice a day for five days
Number of subjects: 11
Study: 8129004

Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg of sparfloxacin
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Multiple daily oral doses totaling 1,000 mg of sparfloxacin
Number of subjects: 36
Study: 2672425

Group type: EXPERIMENTAL
Intervention: GM1
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: GM1 + H
Number of subjects: 502

Group type: COMPARATOR
Intervention: P
Number of subjects: 502

Group type: COMPARATOR
Intervention: P + H
Number of subjects: 502
Study: 798369

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 315

Group type: COMPARATOR
Intervention: IDU
Number of subjects: 315
Study: 31045264

Group type: EXPERIMENTAL
Intervention: Modified MUF (mMUF)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Traditional MUF (tMUF)
Number of subjects: 91
Study: 28814664

Group type: EXPERIMENTAL
Intervention: Carvedilol (low-fixed-dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Carvedilol (dose-escalating)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 25872773

Group type: EXPERIMENTAL
Intervention: Cascade intervention (online cognitive-behavioural therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Peer-support group control
Number of subjects: 120

Group type: COMPARATOR
Intervention: 6-month waitlist control
Number of subjects: 120
Study: 23790995

Group type: EXPERIMENTAL
Intervention: Coaching Boys Into Men program
Number of subjects: 1513

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1513
Study: 22123970

Group type: EXPERIMENTAL
Intervention: Social support from female partner or close female friend during preparation for a stressful task
Number of subjects: 194

Group type: COMPARATOR
Intervention: No social support during preparation for a stressful task
Number of subjects: 194
Study: 19517694

Group type: EXPERIMENTAL
Intervention: Amnioinfusion (AI)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no amnioinfusion)
Number of subjects: 150
Study: 17425628

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg taken 15 min before a high-fat meal (fed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg taken 4 hours before a non-high-fat meal (fasting)
Number of subjects: 0
Study: 15206668

Group type: EXPERIMENTAL
Intervention: Escitalopram (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemic citalopram (60 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Racemic citalopram (20 mg)
Number of subjects: 0
Study: 11847728

Group type: EXPERIMENTAL
Intervention: Balloon-type PEG tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-balloon-type PEG tube
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both types of PEG tubes
Number of subjects: 0
Study: 10023285

Group type: EXPERIMENTAL
Intervention: Intra-articular ketorolac 5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous ketorolac 10 mg
Number of subjects: 60
Study: 8163781

Group type: EXPERIMENTAL
Intervention: 50 mg diphenhydramine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3360541

Group type: EXPERIMENTAL
Intervention: Trampoline exercise program (maximum 109 min/week for 8 weeks)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Trampoline exercise program
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (no trampoline exercise)
Number of subjects: 8
Study: 31618678

Group type: EXPERIMENTAL
Intervention: 6 days of oral flucloxacillin
Number of subjects: 151

Group type: COMPARATOR
Intervention: 12 days of antibiotic therapy (intravenous flucloxacillin followed by placebo)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Modified cure assessment for 6 days of therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Modified cure assessment for 12 days of therapy
Number of subjects: 151
Study: 30551654

Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2 and L. reuteri 12246 with 250 × 10⁶ CFU, 3.33 mg of fructooligosaccharide, and 200 IU of vitamin D₃ (probiotic group)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Vitamin D₃ only (control group)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: L. rhamnosus 19070‐2 and L. reuteri 12246 (probiotic group)
Number of subjects: 168
Study: 27798661

Group type: EXPERIMENTAL
Intervention: Postoperative treatments for cancer
Number of subjects: 17
Study: 24916558

Group type: COMPARATOR
Intervention: Preworkout supplement (SUP) containing caffeine, creatine, β-alanine, amino acids, and B vitamins, ingested daily for 28 days.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preworkout supplement (SUP)
Number of subjects: 0
Study: 23149797

Group type: EXPERIMENTAL
Intervention: Continuously variable dose rate (CVDR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fixed binned dose rates (BDR)
Number of subjects: 10
Study: 20855397

Group type: EXPERIMENTAL
Intervention: Day care management with antibiotic treatment, feeding, and supportive care from 8:00 am to 5:00 pm.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hospital care management with similar 24-hour treatment.
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Day care management.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Hospital care management.
Number of subjects: 360